CN116763702A - 一种淡化深层斑点的组合物及其制备方法与应用 - Google Patents
一种淡化深层斑点的组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN116763702A CN116763702A CN202210230761.0A CN202210230761A CN116763702A CN 116763702 A CN116763702 A CN 116763702A CN 202210230761 A CN202210230761 A CN 202210230761A CN 116763702 A CN116763702 A CN 116763702A
- Authority
- CN
- China
- Prior art keywords
- component
- extract
- parts
- composition
- deep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 238000005562 fading Methods 0.000 title abstract description 25
- 238000002360 preparation method Methods 0.000 title abstract description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 84
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 42
- 239000002537 cosmetic Substances 0.000 claims abstract description 28
- 206010061218 Inflammation Diseases 0.000 claims abstract description 22
- 238000005810 carbonylation reaction Methods 0.000 claims abstract description 21
- 230000004054 inflammatory process Effects 0.000 claims abstract description 20
- 239000003102 growth factor Substances 0.000 claims abstract description 18
- 210000003850 cellular structure Anatomy 0.000 claims abstract description 14
- 230000001737 promoting effect Effects 0.000 claims abstract description 13
- 238000011033 desalting Methods 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims description 60
- 241000717739 Boswellia sacra Species 0.000 claims description 14
- 239000004863 Frankincense Substances 0.000 claims description 14
- 229940108690 glucosyl hesperidin Drugs 0.000 claims description 14
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims description 14
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims description 14
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 12
- 150000001720 carbohydrates Chemical class 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 239000001585 thymus vulgaris Substances 0.000 claims description 12
- ITIMHIATVYROGF-XWUOBKMESA-N (3S)-3-[[(2S)-2-acetamido-6-aminohexanoyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O ITIMHIATVYROGF-XWUOBKMESA-N 0.000 claims description 11
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 11
- JXPHIHWXMBYJAU-UHFFFAOYSA-N 7-methoxy-2,2-dimethyl-3,4-dihydrochromen-6-ol Chemical compound O1C(C)(C)CCC2=C1C=C(OC)C(O)=C2 JXPHIHWXMBYJAU-UHFFFAOYSA-N 0.000 claims description 11
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 11
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 11
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 11
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 11
- 229940117973 dimethylmethoxy chromanol Drugs 0.000 claims description 11
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 claims description 11
- 229940093767 glabridin Drugs 0.000 claims description 11
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 claims description 11
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 claims description 11
- 229940089468 hydroxyethylpiperazine ethane sulfonic acid Drugs 0.000 claims description 11
- 244000288157 Passiflora edulis Species 0.000 claims description 10
- 235000000370 Passiflora edulis Nutrition 0.000 claims description 10
- 239000000413 hydrolysate Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 claims description 9
- VNXWANZMRATDQM-UHFFFAOYSA-N 2-(2-phenylethyl)benzene-1,3-diol Chemical compound OC1=CC=CC(O)=C1CCC1=CC=CC=C1 VNXWANZMRATDQM-UHFFFAOYSA-N 0.000 claims description 9
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 239000003906 humectant Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 239000002562 thickening agent Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 4
- 108010087806 Carnosine Proteins 0.000 claims description 4
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- 229940044199 carnosine Drugs 0.000 claims description 4
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 4
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 claims description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960004889 salicylic acid Drugs 0.000 claims description 4
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 3
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 3
- 239000004902 Softening Agent Substances 0.000 claims description 3
- 229940084779 albizia julibrissin bark extract Drugs 0.000 claims description 3
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 3
- 229940036350 bisabolol Drugs 0.000 claims description 3
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- -1 polydimethylsiloxane Polymers 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 2
- RRJOMESUBQAYOA-BZSNNMDCSA-N (2S)-2-[[(2S)-2-[[2-[[(2S)-2-acetamido-6-aminohexanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-6-aminohexanamide Chemical group NCCCC[C@H](NC(=O)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)CC1=CN=CN1 RRJOMESUBQAYOA-BZSNNMDCSA-N 0.000 claims description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 2
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 claims description 2
- 244000298715 Actinidia chinensis Species 0.000 claims description 2
- 235000009434 Actinidia chinensis Nutrition 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims description 2
- SBLKVIQSIHEQOF-UPHRSURJSA-N Octadec-9-ene-1,18-dioic-acid Chemical compound OC(=O)CCCCCCC\C=C/CCCCCCCC(O)=O SBLKVIQSIHEQOF-UPHRSURJSA-N 0.000 claims description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 2
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 229940116224 behenate Drugs 0.000 claims description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 claims description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000005487 catechin Nutrition 0.000 claims description 2
- 229940059958 centella asiatica extract Drugs 0.000 claims description 2
- 229950001002 cianidanol Drugs 0.000 claims description 2
- 229940105990 diglycerin Drugs 0.000 claims description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 2
- XJFGDLJQUJQUEI-UHFFFAOYSA-N dodecyl decanoate dodecyl octanoate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCC.CCCCCCCCCCCCOC(=O)CCCCCCCCC XJFGDLJQUJQUEI-UHFFFAOYSA-N 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 229940093497 ergothioneine Drugs 0.000 claims description 2
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 229940116918 octadecenedioic acid Drugs 0.000 claims description 2
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 claims description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 235000021283 resveratrol Nutrition 0.000 claims description 2
- 229940016667 resveratrol Drugs 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 claims description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 240000002657 Thymus vulgaris Species 0.000 claims 4
- 240000002547 Rosa roxburghii Species 0.000 claims 1
- 235000000640 Rosa roxburghii Nutrition 0.000 claims 1
- 244000273928 Zingiber officinale Species 0.000 claims 1
- 235000006886 Zingiber officinale Nutrition 0.000 claims 1
- 235000008397 ginger Nutrition 0.000 claims 1
- 229940057910 shea butter Drugs 0.000 claims 1
- 239000001841 zingiber officinale Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 210000004027 cell Anatomy 0.000 abstract description 14
- 230000003213 activating effect Effects 0.000 abstract description 4
- 201000004624 Dermatitis Diseases 0.000 abstract description 2
- 230000006315 carbonylation Effects 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 35
- 238000012360 testing method Methods 0.000 description 31
- 210000004207 dermis Anatomy 0.000 description 13
- 150000004676 glycans Chemical class 0.000 description 12
- 229920001282 polysaccharide Polymers 0.000 description 12
- 239000005017 polysaccharide Substances 0.000 description 12
- 208000003351 Melanosis Diseases 0.000 description 11
- 240000000260 Typha latifolia Species 0.000 description 10
- 206010042496 Sunburn Diseases 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 241000246358 Thymus Species 0.000 description 8
- 230000008021 deposition Effects 0.000 description 8
- 206010008570 Chloasma Diseases 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 210000002469 basement membrane Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000002752 melanocyte Anatomy 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 230000002087 whitening effect Effects 0.000 description 5
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- 230000032677 cell aging Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 230000005808 skin problem Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- DWVXFVWWARTDCQ-UHFFFAOYSA-N 2-ethylbenzene-1,3-diol Chemical compound CCC1=C(O)C=CC=C1O DWVXFVWWARTDCQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 206010043189 Telangiectasia Diseases 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000887 face Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- IMMBLRJLSYJQIZ-UNQGIHKMSA-N (2S)-7-[3,4-dihydroxy-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl]oxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one Chemical compound COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(OC3OC(COC4OC(C)C(O)C(O)C4O)C(OC4OC(CO)C(O)C(O)C4O)C(O)C3O)cc2O1 IMMBLRJLSYJQIZ-UNQGIHKMSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- RNMDNPCBIKJCQP-UHFFFAOYSA-N 5-nonyl-7-oxabicyclo[4.1.0]hepta-1,3,5-trien-2-ol Chemical compound C(CCCCCCCC)C1=C2C(=C(C=C1)O)O2 RNMDNPCBIKJCQP-UHFFFAOYSA-N 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 108010002255 deoxyhemoglobin Proteins 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229940051810 licorice root extract Drugs 0.000 description 1
- 235000020725 licorice root extract Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940074122 phyllanthus emblica fruit extract Drugs 0.000 description 1
- 235000020744 piper nigrum extract Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001180 sulfating effect Effects 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
本发明属于化妆品技术领域，具体涉及一种淡化深层斑点的组合物及其制备方法与应用。该淡化深层斑点的组合物，包括以下重量份的组分：0.03‑1.5份抑制炎症组分A，0.1‑5份抑制黑色素组分B，0.03‑2.01份抗糖化组分C，0.03‑3份抗羰基化组分D，0.03‑1份活化细胞组分E、0.01‑0.5份内源性促进生长因子生成的组分F。通过搭配抑制皮肤的炎症、抑制黑色素、抗糖化、抗羰基化、促进细胞更新、活化基底层细胞活力、促进TGF‑β生长因子生成等多方面组合物，从而实现具有对皮肤安全、温和无刺激、修复效果好、真正淡化深层斑点的效果。
Description
技术领域
本发明属于化妆品技术领域，具体涉及一种淡化深层斑点的组合物及其制备方法与应用。
背景技术
色斑，是指生长在皮肤上且与周围肌肤颜色不同的斑点。色斑包括雀斑、黑斑、黄褐斑和老年斑，属于色素障碍性皮肤病。色斑多发于面颊和前额部位。导致色斑形成的原因有多种，如日晒、使用劣质化妆品、压力、睡眠不足等。
皮肤分成“表皮层”和“真皮层”，为了对抗阳光中的紫外线，我们的“表皮层”的最深处，有一些“黑色素细胞”，专门生产“黑色素”来吸收紫外线。“黑色素”生产出来之后，就会被交给“表皮层”中的“角质细胞”，而这些“角质细胞”会逐渐向皮肤最表层走，最终脱落。也就是说，只要皮肤工作正常，所有生产出来的“黑色素”，都会慢慢脱落掉，不应该长期停留在皮肤里面。所以淡斑产品想要表现出好的效果，都须要综合考虑怎样抑制皮肤的炎症、抑制黑色素、抗糖化、抗羰基化、促进细胞更新（增强细胞的水份、营养均衡，增强皮肤的微循环，加速肌肤的新陈代谢，来促进表皮细胞的更新，从而加速代谢黑色素的过程）、防晒等因素，这几方面缺一不可。
如图1所示（源自：Noblesse E， Nizard C， Cario-André M， Lepreux S， PainC， Schnebert S， Taïeb A，Kurfurst R.Skin ultrastructure in senile lentigo.SkinPharmacol Physiol. 006;19(2):95-100. doi: 10.1159/000091976. Epub 2006 May 9.PMID: 16685148.），老年斑（主要是光老化——晒斑）病变后，表皮层厚度有增加；基底层色素沉着过度更明显，黑色素细胞下垂明显；随着病变的发展，即病变阶段2、3可观察到嵌入真皮层的黑色素细胞分泌出来的黑色素漏到了真皮层。
如图2所示（源自：Grimes PE，Yamada N，Bhawan J.Light microscopic，immunohistochemical，and ultrastructural alterations in patients withmelasma.Am J Dermatopathol.2005Apr;27(2):96-101.doi:10.1097/01.dad.0000154419.18653.2e.PMID:15798432.），黄褐斑病变后，角质层变薄；基底膜破损和真皮弹性变差；真皮血管变多、变大（血管中脱氧血红蛋白积累），这体现出类似黑色素类的表现。
目前市面上的大部分淡斑产品多以单一高浓度的方式对黑色素细胞的抑制并加速正常肌肤的美白进程来淡斑，对于斑点皮肤微观结构并没有进行深入探讨分析。而对于由上述斑点区域伴随着的基底膜和真皮层残缺或细胞老化导致的黑色素沉积问题，鲜有文献资料报道；现有技术亦无适宜的解决方案。
例如，中国专利CN104800135B公开了一种兼具淡斑、保湿、防晒的中药化妆品，可有效解决兼具淡斑、保湿、防晒用化妆品的问题，方法是，由以下重量百分比计的原料混合均匀制成：人参提取物5-10%、天冬提取物0.1-1%、红花提取物5-10%、鸡冠花提取物5-20%、抗坏血酸2-3%、橄榄油12-17%、棕榈酸异丙酯4-6%、聚氧乙烯壬基酚醚0.4-0.6%、甘油4-6%、对羟基苯甲酸甲酯0.08-0.12%、乙醇6-8%，余量为去离子水，本发明组方科学合理，具有补气养阴，活血祛瘀、保湿美白、强体防晒，能有效清除自由基、抑制酪氨酸酶的活性、加强皮肤新陈代谢，减少紫外线对皮肤的伤害，天然无刺激，达到全面美白皮肤的功效。
中国专利CN104042559B公开了一种具有美白淡斑功效的天然组合物和天然化妆品，所述组合物主要由下述重量份的组分组成：光果甘草根提取物0.05-0.2份，余甘子果实提取物0.1-2份，抗坏血酸葡糖苷0.1-2份，红没药醇0.1-0.5份，黑胡椒提取物0.1-0.4份，酵母提取物1-15份。
中国专利CN110713551B公开了一种多糖、硫酸化多糖和在美白淡斑化妆品中的应用。本发明从金钱蒲全草中制备得到了一种多糖含量在95％左右的金钱蒲多糖，并对其衍生化修饰得到一种硫酸化金钱蒲多糖。酪氨酸酶抑制活性测试结果表明，金钱蒲多糖对酪氨酸酶具有较高的抑制作用，将金钱蒲多糖硫酸化修饰得到的硫酸化金钱蒲多糖对酪氨酸酶的抑制作用更强，抑制强度提高了80％以上，金钱蒲多糖及其衍生化产物硫酸化金钱蒲多糖都具有用作化妆品添加剂提高化妆品美白淡斑效果的前景。
然上述专利均未对由斑点区域伴随着的基底膜和真皮层残缺或细胞老化导致的黑色素沉积问题提出适宜的解决方案。
发明内容
为了解决现有技术中存在的问题，本发明的目的在于提供一种淡化深层斑点的组合物及其制备方法与应用，能够改善由斑点区域伴随着的基底膜和真皮层残缺或细胞老化导致的黑色素沉积，具有对皮肤安全、温和无刺激、修复效果好、真正淡化深层斑点的效果。
本发明的技术方案是：
一种淡化深层斑点的组合物，包括以下重量份的组分：0.03-1.5份抑制炎症组分A，0.1-5份抑制黑色素组分B，0.03-2.01份抗糖化组分C，0.03-3份抗羰基化组分D，0.03-1份活化细胞组分E，0.01-0.5份内源性促进生长因子生成的组分F。
进一步地，所述的淡化深层斑点的组合物，由以下重量份的组分组成：1份抑制炎症组分A，1份抑制黑色素组分B，2.01份抗糖化组分C，1份抗羰基化组分D，2.4份活化细胞组分E，0.03份内源性促进生长因子生成的组分F。
通过对皮肤超微结构进行深入分析，发现斑点区域还伴随着基底膜和真皮层残缺、细胞老化等现象，致使黑素色沉积，尤其是基底膜和真皮层的残缺，会使黑素色无法随皮肤正常代谢排出体外。故本发明从多角度出发，通过添加抑制炎症组分，一是减少由表皮炎症反应导致的炎症因子（比如花生四烯酸AA/前列腺素PG/白三烯LT/碱性成纤维细胞生长因子BFGF/白细胞介素-1IL-1/内皮素ET/一氧化氮NO）分泌增多而激活黑色素细胞（使黑色素细胞亢奋）导致的色素沉着增加；二是减少VEGF和MMP等物质的合成而导致的皮肤毛细血管扩张；通过添加抑制黑色素组分（从抑制生成、阻止运输和加速代谢方面共同进行）针对表皮层黑色素设计多靶点达到减少黑色素的效果；通过添加抗糖化组分、抗羰基化组分减少皮肤真皮层蛋白质非酶糖基化反应、羰基化反应所产生的AGEs褐变和脂褐素堆积，从而达到从皮肤深层减少皮肤色素沉着的效果；并通过添加活化细胞组分、内源性促进生长因子生成的组分来活化基底层细胞、保持细胞活力。色斑表面看到的是黑色素的堆积，隐藏在下面的是皮肤老化、炎症、屏障受损、血管增生等一系列皮肤问题，只有全面考虑黑素色形成、沉积原因从而有针对性的设计组合物来促进滞留在皮肤深层的黑色素排出，从此实现协同增效淡化和预防斑点的生成的效果。
进一步地，所述抑制炎症组分A为尿囊素、甘草酸二钾、乳香提取物、紫檀芪、葡糖基橙皮苷、红没药醇、硬脂醇甘草亭酸酯、刺梨果提取物、积雪草提取物、姜根提取物、牛油果树果脂提取物、糖类水解物中的一种或多种；
抑制黑色素组分B为紫檀芪、白藜芦醇、4-丁基间苯二酚、苯乙基间苯二酚、十八碳烯二酸、中华猕猴桃提取物、水解欧洲李提取物、欧百里香提取物、VC及其衍生物、光甘草定中的一种或多种；
抗糖化组分C为肌肽、脱羧肌肽、乙酰基四肽-2、合欢树皮提取物、石榴籽提取物、麦角硫因、EGCG儿茶素及其类似物中的一种或多种；
抗羰基化组分D为二甲基甲氧基苯并二氢吡喃醇；
活化细胞组分E为辅酶Q10、烟酰胺、水杨酸、鸡蛋果提取物、葡糖基橙皮苷、地黄提取物、乳香提取物、咖啡因、水杨酸、羟乙基哌嗪乙烷磺酸、中华猕猴桃提取物中的一种或多种；
内源性促进生长因子生成的组分F为EGF及其类似物、乙酰化透明质酸、纤细老鹳草提取物、多肽中的一种或多种。
更进一步地，所述抑制炎症组分A为葡糖基橙皮苷、乳香提取物和糖类水解物；
抑制黑色素组分B为紫檀芪、苯乙基间苯二酚、光甘草定和欧百里香；
抗糖化组分C为乙酰基四肽-2和合欢树皮提取物；
抗羰基化组分D为二甲基甲氧基苯并二氢吡喃醇；
活化细胞组分E为辅酶Q10、鸡蛋果提取物和羟乙基哌嗪乙烷磺酸；
内源性促进生长因子生成的组分F为棕榈酰三肽-5。
进一步地，所述抑制炎症组分A为0.3-0.5份葡糖基橙皮苷、0.4-0.6份乳香提取物、0.05-0.15份糖类水解物组合；
抑制黑色素组分B为0.4-0.6份紫檀芪、0.2-0.4份苯乙基间苯二酚、0.05-0.15份光甘草定、0.05-0.15份欧百里香；
抗糖化组分C为0.01-0.02份乙酰基四肽-2、1-3份合欢树皮提取物组合；
抗羰基化组分D为二甲基甲氧基苯并二氢吡喃醇；
活化细胞组分E为0.2-0.4份辅酶Q10、0.05-0.15份鸡蛋果提取物、1-3份羟乙基哌嗪乙烷磺酸组合；
内源性促进生长因子生成的组分F为棕榈酰三肽-5。
更进一步地，所述抑制炎症组分A为0.4份葡糖基橙皮苷、0.5份乳香提取物、0.1份糖类水解物组合；
抑制黑色素组分B为0.5份紫檀芪、0.3份苯乙基间苯二酚、0.1份光甘草定、0.1份欧百里香；
抗糖化组分C为0.01份乙酰基四肽-2、2份合欢树皮提取物组合；
抗羰基化组分D为二甲基甲氧基苯并二氢吡喃醇；
活化细胞组分E为0.3份辅酶Q10、0.1份鸡蛋果提取物、2份羟乙基哌嗪乙烷磺酸组合；
内源性促进生长因子生成的组分F为棕榈酰三肽-5。
上述组合有增强细胞的水份、营养均衡，增强皮肤的微循环，加速肌肤的新陈代谢来促进表皮细胞的更新的功能。而且，该组合可以修复基底膜和残缺真皮层，使得残缺的基底膜和真皮层重新参与正常代谢活动，从而将沉积的黑色素排出体外。
本发明还提供了一种淡化深层斑点的化妆品，包括权利要求上述的淡化深层斑点的组合物。
进一步地，所述的淡化深层斑点的化妆品包括以下组分：所述淡化深层斑点的组合物、增稠剂、保湿剂、乳化剂、柔润剂、防腐剂和水。
进一步地，增稠剂是黄原胶和聚丙烯酸酯交联聚合物-6；
保湿剂是甘油、戊二醇和双甘油；
乳化剂是聚甘油-6 硬脂酸酯、甘油硬脂酸酯、鲸蜡硬脂醇和聚甘油-6山嵛酸酯；
柔润剂是甘油三（乙基己酸）酯、C12-15 醇苯甲酸酯、聚二甲基硅氧烷和椰油醇-辛酸酯/癸酸酯。
而且，本发明还提供了一种所述的淡化深层斑点的化妆品制备方法，制备方法包括以下步骤：
（1）按照配比准确称量原料成分；
（2）将增稠剂、保湿剂和水混合，搅拌溶解并加热至80-85℃，得到A相；
（3）将乳化剂、柔润剂、所述淡化深层斑点的组合物中的油溶成分预混后加入到步骤（2）得到的A相中，均质搅拌均匀，降温至50℃，得到B相；
（4）将所述淡化深层斑点的组合物中的水溶成分和防腐剂加入步骤（3）得到的B相中，搅拌溶解均匀，得到产品。
所述淡化深层斑点的组合物中油溶成分为乳香提取物、紫檀芪、乙基间苯二酚、光甘草定、二甲基甲氧基苯并二氢吡喃醇、辅酶Q10；
所述淡化深层斑点的组合物中水溶成分为葡糖基橙皮苷、糖类水解物、欧百里香、乙酰基四肽-2、合欢树皮提取物、鸡蛋果提取物、羟乙基哌嗪乙烷磺酸、棕榈酰三肽-5。
本发明针对表皮层黑色素设计多靶点，并在活化基底层细胞、保持细胞活力方面设计组合物来促进滞留在皮肤深层的黑色素排出，从而实现协同增效淡化和预防斑点的生成的效果。
与现有技术相比，本发明提供的一种淡化深层斑点的组合物及其制备方法与应用，具有以下优势：
（1）本发明通过添加抑制炎症组分，一是有效减少由表皮炎症反应导致的炎症因子分泌增多而激活黑色素细胞导致的色素沉着增加；二是有效减少VEGF和MMP等物质的合成而导致的皮肤毛细血管扩张；通过添加抑制黑色素组分从抑制生成、阻止运输和加速代谢方面共同进行，针对表皮层黑色素设计多靶点达到减少黑色素的效果；并通过添加抗糖化组分、抗羰基化组分减少皮肤真皮层蛋白质非酶糖基化反应、羰基化反应所产生的AGEs褐变和脂褐素堆积，从而达到从皮肤深层减少皮肤色素沉着的效果；且通过添加活化细胞组分、内源性促进生长因子生成的组分来活化基底层细胞、保持细胞活力。本发明全面考虑黑素色形成、沉积原因从而有针对性的设计组合物，通过解决深层次的皮肤老化、炎症、屏障受损、血管增生等一系列皮肤问题，进而来促进滞留在皮肤深层的黑色素排出，从此实现协同增效淡化和预防斑点的生成的效果。
（2）通过图3-5可以看出，本发明所得淡化深层斑点的化妆品淡斑具有明显改善效果。由受试者在测试过程中的VISIA局部标光图及棕色斑图可知，在试用期的第14d即可有效淡化晒斑。
（3）本发明所得的淡化深层斑点的化妆品安全性好，对皮肤无严重不良反应。
附图说明
图1为正常皮肤和老年斑病变图；
图2为黄褐斑病变图；
图3为面部有晒斑的志愿者（一）所拍的VISIA局部标光图及棕色斑图，第一列图片为使用前图片，第二列为试用2周的图片，第三列为试用4周的图片，第四列为试用6周的图片，第五列为试用8周的图片；
图4为面部有晒斑的志愿者（二）所拍的VISIA局部标光图及棕色斑图，第一列图片为使用前图片，第二列为试用1周的图片，第三列为试用2周的图片，第四列为试用4周的图片；
图5为面部有晒斑的志愿者（一）所拍的VISIA局部标光图及棕色斑图，第一列图片为使用前图片，第二列为试用2周的图片，第三列为试用4周的图片，第四列为试用6周的图片。
具体实施方式
以下通过具体实施方式的描述对本发明作进一步说明，但这并非是对本发明的限制，本领域技术人员根据本发明的基本思想，可以做出各种修改或改进，但是只要不脱离本发明的基本思想，均在本发明的保护范围之内。
其中，本发明所用试剂葡糖基橙皮苷（Alpha Glucosyl Hesperidin）购自Hayashibara Co.，Ltd；乳香提取物（Boswellia serrata extract）购自Sabinsacorporation；糖类水解物（Sweetone）购自Laboratoires Expanscience；紫檀芪购自Sabinsa corporation；欧百里香提取物（CinderellaCare）购自ICHIMARU PHARCOS Co.，Ltd；鸡蛋果提取物购自CHIMARU PHARCOS Co.，Ltd；合欢树皮提取物购自Sederma。其余试剂均为常用试剂，均可在常规试剂生产销售公司购买。
实施例中原料组分的“份”代表“重量份数”。
本发明实施例1~3的淡化深层斑点的化妆品配方如下表所示：
表1 配方表
注：表中原料组分的用量为“重量份数”，每组用量均为100重量份。
所述抑制炎症组分A为0.4份葡糖基橙皮苷、0.5份乳香提取物和0.1份糖类水解物的混合物；
抑制黑色素组分B为0.5份紫檀芪、0.3份苯乙基间苯二酚、0.1份光甘草定、0.1份欧百里香提取物的混合物；
抗糖化组分C为0.01份乙酰基四肽-2和2份合欢树皮提取物的混合物；
抗羰基化组分D为二甲基甲氧基苯并二氢吡喃醇；
活化细胞组分E为0.3份辅酶Q10、0.1份鸡蛋果提取物和2份羟乙基哌嗪乙烷磺酸的混合物；
内源性促进生长因子生成的组分F为棕榈酰三肽-5。
实施例1-3 一种淡化深层斑点的化妆品
淡斑化妆品的制备方法如下：
（1）按照配比准确称量原料成分；
（2）将增稠剂、保湿剂和水混合，搅拌溶解并加热至80-85℃，得到A相；
（3）将乳化剂、柔润剂、所述淡化深层斑点的组合物中的油溶成分预混后加入到步骤（2）得到的A相中，均质搅拌均匀，降温至50℃，得到B相；
（4）将所述淡化深层斑点的组合物中的水溶成分和防腐剂加入步骤（3）得到的B相中，搅拌溶解均匀，得到产品。
所述淡化深层斑点的组合物中油溶成分为乳香提取物、紫檀芪、乙基间苯二酚、光甘草定、二甲基甲氧基苯并二氢吡喃醇、辅酶Q10；
所述淡化深层斑点的组合物中水溶成分为葡糖基橙皮苷、糖类水解物、欧百里香、乙酰基四肽-2、合欢树皮提取物、鸡蛋果提取物、羟乙基哌嗪乙烷磺酸、棕榈酰三肽-5。
本发明对比例和对照组的淡化深层斑点的化妆品配方如下表所示：
表2 配方表
注：表中原料组分的用量为“重量份数”，每组用量均为100重量份。
各对比例中所述抑制炎症组分A、抑制黑色素组分B、抗糖化组分C、抗羰基化组分D、活化细胞组分E和内源性促进生长因子生成的组分F的具体原料、用量与实施例相同。
试验例一、温和性测试
测试依据：根据化妆品安全技术规范2015版，人体皮肤斑贴试验
试验方法：采用24h封闭式斑贴试验。
邀请健康志愿者300名，年龄20~59岁，无过敏史。
选择面积不超过50mm2，深度约为1mm的合适斑试器，分别称取实施例组、对比例组和对照组产品0.020~0.025ml至斑试器中。清洁受试者背部后，将加有上述产品的斑试器贴敷于受试者前臂曲侧，持续24h。受试者24h内保持斑贴部位干燥，避免激烈运动、挠抓斑试部位、长时间日光照射等。24h后去除斑试器并做好标记，30min后等压痕消失后在充足灯光下进行判定。皮肤不良反应分级标准如表3所示，各产品的皮肤不良反应结果如表4所示。
表3 皮肤不良反应分级标准
表4 样品斑贴测试结果
本发明实施例组和对比例组，对照例对皮肤均无严重不良反应，300例受试者无阳性反应，本发明的淡斑组合物的安全性好。
试验例二、黄褐斑淡斑测试效果
实验步骤：
1、测试人群：17-50岁皮肤有黄褐斑的受试者，男女各一半，共80人，分为10组，每组8名。
测试方法：受试者随机分组，分别在面部试用实施例组、对比例组和对照组的样品(每组分别使用一种样品)；用量为1.5g/次，2次/天(早晚各1次)，连续使用一个月。
判断标准分为三大程度：斑点明显淡化、斑点稍微淡化有效、黄褐斑无改变，测试结果见下表。
表5测试自评结果
根据测试结果，本发明实施例组所制备的淡斑化妆品均具有较好的淡化斑点的效果，其中实施例1为最佳配方（基于成本考虑）。进一步分析对比例1-6的测试结果可知，缺少任意一种或多种淡化斑点组合物组分时，产品的祛斑效果都出现明显下降，说明组分复配，可协同淡斑的效果。
试验例三、晒斑淡斑测试效果
筛选30名脸上有晒斑的志愿者，选择面部作为测试部位。测试周期为56天，在使用样品前1天和使用后第14、28、42、56天，观察志愿者面部晒斑消退情况。测试前1周为洗脱期，此期间受试者使用不含任何活性物的基础保湿水和保湿乳，在测试期间不能使用其他美白产品。受试者连续56天使用实施例1的样品，每天早晨、晚上睡前洗脸后在面部涂抹样品，涂抹量约为0.2g，重点部位取0.1g重复涂抹。
测试方法：以VISIA局部标光图及棕色斑图评估使用前后脸部斑点的变化情况，采用5段法评估：明显改善-稍微改善-不变-稍微恶化-明显恶化。
表6淡斑效果，明显改善
由上表结果可知，本发明实施例1所得的淡化深层斑点的化妆品淡斑效果较优，其中三个具有明显改善效果的受试者在测试过程中的VISIA局部标光图及棕色斑图分别如图3、图4、图5所示，通过图3-5可以看出，本发明实施例1所得的淡化深层斑点的化妆品均在第14d即可有效淡化晒斑。
如图3所示，回访测试第2周时，从棕色斑图可看见棕色斑有部分色素淡化且面积变小；回访测试第8周时，棕色斑图可见深色斑点色素明显变浅且面积变小，底色色沉面积同样明显变小且颜色变淡，VISA标光图可见斑点面积也显著变小，颜色也明显变浅，棕色斑图和VISA标光图的结果均说明本发明实施例1所得的淡化深层斑点的化妆品在使用时淡斑效果尤为显著。
如图4所示，结合VISA标光图和棕色斑点图分析，试用者试用1周即可观察到斑点色沉有所淡化；第2周时，有局部斑点颜色已经开始淡化且面积变小，较多斑点聚集处，界面开始变清晰；到第4周时，可观察到斑点明显变浅、面积变小，面部的光泽度也增加了，说明本发明实施例1所得的淡化深层斑点的化妆品具有显著的淡斑效果。
如图5所示，回访测试第2周时，由棕色斑图可见大部分斑点颜色变淡，色素集中点色素有分散开，斑点面积开始变小，由VISA标光图可见斑点同样开始面积变小，颜色也开始变淡；测试回访的第4周时，棕色斑图和VISA标光图都可看出，有5成的斑点已经明显淡化，且面积较大的色沉均有淡化且面积变小；试用者持续使用6周后，从棕色斑点图和VISA标光图来看，色沉色素均有明显下降，局部斑点色素集中点也明显分散，面积也有较大所缩减。这进一步证明本发明实施例1所得的淡化深层斑点的化妆品具有显著的淡斑效果。
综上所述，本发明全面考虑黑素色形成、沉积原因从而有针对性的设计组合物，通过解决深层次的皮肤老化、炎症、屏障受损、血管增生等一系列皮肤问题，进而来促进滞留在皮肤深层的黑色素排出，从此实现协同增效淡化和预防斑点的生成的效果。
上述实施例仅例示性说明本发明的原理及其功效，而非用于限制本发明。任何熟悉此技术的人士皆可在不违背本发明的精神及范畴下，对上述实施例进行修饰或改变。因此，举凡所属技术领域中具有通常知识者在未脱离本发明所揭示的精神与技术思想下所完成的一切等效修饰或改变，仍应由本发明的权利要求所涵盖。
Claims (10)
1.一种淡化深层斑点的组合物，其特征在于，包括以下重量份的组分：0.03-1.5份抑制炎症组分A，0.1-5份抑制黑色素组分B，0.03-2.01份抗糖化组分C，0.03-3份抗羰基化组分D，0.03-1份活化细胞组分E，0.01-0.5份内源性促进生长因子生成的组分F。
2.如权利要求1所述的淡化深层斑点的组合物，其特征在于，由以下重量份的组分组成：1份抑制炎症组分A，1份抑制黑色素组分B，2.01份抗糖化组分C，1份抗羰基化组分D，2.4份活化细胞组分E，0.03份内源性促进生长因子生成的组分F。
3.如权利要求1或2所述的淡化深层斑点的组合物，其特征在于，所述抑制炎症组分A为尿囊素、甘草酸二钾、乳香提取物、紫檀芪、葡糖基橙皮苷、红没药醇、硬脂醇甘草亭酸酯、刺梨果提取物、积雪草提取物、姜根提取物、牛油果树果脂提取物、糖类水解物中的一种或多种；
抑制黑色素组分B为紫檀芪、白藜芦醇、4-丁基间苯二酚、苯乙基间苯二酚、十八碳烯二酸、中华猕猴桃提取物、水解欧洲李提取物、欧百里香提取物、VC及其衍生物、光甘草定中的一种或多种；
抗糖化组分C为肌肽、脱羧肌肽、乙酰基四肽-2、合欢树皮提取物、石榴籽提取物、麦角硫因、EGCG儿茶素中的一种或多种；
抗羰基化组分D为二甲基甲氧基苯并二氢吡喃醇；
活化细胞组分E为辅酶Q10、烟酰胺、水杨酸、鸡蛋果提取物、葡糖基橙皮苷、地黄提取物、乳香提取物、咖啡因、水杨酸、羟乙基哌嗪乙烷磺酸、中华猕猴桃提取物中的一种或多种；
内源性促进生长因子生成的组分F为EGF、乙酰化透明质酸、纤细老鹳草提取物、多肽中的一种或多种。
4.如权利要求3所述的淡化深层斑点的组合物，其特征在于，所述抑制炎症组分A为葡糖基橙皮苷、乳香提取物和糖类水解物；
抑制黑色素组分B为紫檀芪、苯乙基间苯二酚、光甘草定和欧百里香；
抗糖化组分C为乙酰基四肽-2和合欢树皮提取物；
抗羰基化组分D为二甲基甲氧基苯并二氢吡喃醇；
活化细胞组分E为辅酶Q10、鸡蛋果提取物和羟乙基哌嗪乙烷磺酸；
内源性促进生长因子生成的组分F为棕榈酰三肽-5。
5.如权利要求4所述的淡化深层斑点的组合物，其特征在于，所述抑制炎症组分A为0.3-0.5份葡糖基橙皮苷、0.4-0.6份乳香提取物、0.05-0.15份糖类水解物组合；
抑制黑色素组分B为0.4-0.6份紫檀芪、0.2-0.4份苯乙基间苯二酚、0.05-0.15份光甘草定、0.05-0.15份欧百里香；
抗糖化组分C为0.01-0.02份乙酰基四肽-2、1-3份合欢树皮提取物组合；
抗羰基化组分D为二甲基甲氧基苯并二氢吡喃醇；
活化细胞组分E为0.2-0.4份辅酶Q10、0.05-0.15份鸡蛋果提取物、1-3份羟乙基哌嗪乙烷磺酸组合；
内源性促进生长因子生成的组分F为棕榈酰三肽-5。
6.如权利要求4所述的淡化深层斑点的组合物，其特征在于，所述抑制炎症组分A为0.4份葡糖基橙皮苷、0.5份乳香提取物、0.1份糖类水解物组合；
抑制黑色素组分B为0.5份紫檀芪、0.3份苯乙基间苯二酚、0.1份光甘草定、0.1份欧百里香；
抗糖化组分C为0.01份乙酰基四肽-2、2份合欢树皮提取物组合；
抗羰基化组分D为二甲基甲氧基苯并二氢吡喃醇；
活化细胞组分E为0.3份辅酶Q10、0.1份鸡蛋果提取物、2份羟乙基哌嗪乙烷磺酸组合；
内源性促进生长因子生成的组分F为棕榈酰三肽-5。
7.一种淡化深层斑点的化妆品，其特征在于，包括权利要求1-6任一所述的淡化深层斑点的组合物。
8.如权利要求7所述的淡化深层斑点的化妆品，其特征在于，包括以下组分：所述淡化深层斑点的组合物、增稠剂、保湿剂、乳化剂、柔润剂、防腐剂和水。
9.如权利要求8所述的淡化深层斑点的化妆品，其特征在于，
增稠剂是黄原胶和聚丙烯酸酯交联聚合物-6；
保湿剂是甘油、戊二醇和双甘油；
乳化剂是聚甘油-6 硬脂酸酯、甘油硬脂酸酯、鲸蜡硬脂醇和聚甘油-6山嵛酸酯；
柔润剂是甘油三（乙基己酸）酯、C12-15 醇苯甲酸酯、聚二甲基硅氧烷和椰油醇-辛酸酯/癸酸酯。
10.一种如权利要求8或9所述的淡化深层斑点的化妆品制备方法，其特征在于，制备方法包括以下步骤：
（1）按照配比准确称量原料成分；
（2）将增稠剂、保湿剂和水混合，搅拌溶解并加热至80-85℃，得到A相；
（3）将乳化剂、柔润剂、所述淡化深层斑点的组合物中的油溶成分预混后加入到步骤（2）得到的A相中，均质搅拌均匀，降温至50℃，得到B相；
（4）将所述淡化深层斑点的组合物中的水溶成分和防腐剂加入步骤（3）得到的B相中，搅拌溶解均匀，得到产品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210230761.0A CN116763702A (zh) | 2022-03-10 | 2022-03-10 | 一种淡化深层斑点的组合物及其制备方法与应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210230761.0A CN116763702A (zh) | 2022-03-10 | 2022-03-10 | 一种淡化深层斑点的组合物及其制备方法与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116763702A true CN116763702A (zh) | 2023-09-19 |
Family
ID=88006809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210230761.0A Pending CN116763702A (zh) | 2022-03-10 | 2022-03-10 | 一种淡化深层斑点的组合物及其制备方法与应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116763702A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117257693A (zh) * | 2023-11-21 | 2023-12-22 | 宝萃生物科技有限公司 | 具有即时美白保湿功效的余甘子啫喱面膜及其制备方法 |
| CN117797040A (zh) * | 2023-12-29 | 2024-04-02 | 济宁环聚医药科技有限公司 | 含4-丁基间苯二酚的美白纳米乳液及其制备方法 |
| CN117797040B (zh) * | 2023-12-29 | 2024-06-04 | 济宁环聚医药科技有限公司 | 含4-丁基间苯二酚的美白纳米乳液及其制备方法 |
-
2022
- 2022-03-10 CN CN202210230761.0A patent/CN116763702A/zh active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117257693A (zh) * | 2023-11-21 | 2023-12-22 | 宝萃生物科技有限公司 | 具有即时美白保湿功效的余甘子啫喱面膜及其制备方法 |
| CN117257693B (zh) * | 2023-11-21 | 2024-01-30 | 宝萃生物科技有限公司 | 具有即时美白保湿功效的余甘子啫喱面膜及其制备方法 |
| CN117797040A (zh) * | 2023-12-29 | 2024-04-02 | 济宁环聚医药科技有限公司 | 含4-丁基间苯二酚的美白纳米乳液及其制备方法 |
| CN117797040B (zh) * | 2023-12-29 | 2024-06-04 | 济宁环聚医药科技有限公司 | 含4-丁基间苯二酚的美白纳米乳液及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9770404B2 (en) | Cosmetic composition for whitening and improving the resilience of skin | |
| US10124030B2 (en) | Skincare preparations | |
| CN111529417B (zh) | 一种具有抗蓝光功效修护眼霜及其制备方法 | |
| Kwon et al. | Conditioned medium from human bone marrow‐derived mesenchymal stem cells promotes skin moisturization and effacement of wrinkles in UVB‐irradiated SKH‐1 hairless mice | |
| CN103816095A (zh) | 高级糖化终产物的去糖化 | |
| CN110302135A (zh) | 一种温和祛痘霜 | |
| CA3062635A1 (en) | Topical muscadine formulation for cosmetic use | |
| CN112587456B (zh) | 一种修护美白组合物及其制备方法 | |
| CN110430865A (zh) | 包含桦褐孔菌提取物的化妆品组合物及其用途 | |
| JP2018027965A (ja) | 皮膚バリア機能を改善するのに有用なホホバ抽出物 | |
| KR101098400B1 (ko) | 홍삼 먹인 달팽이 점액의 제조방법 및 이를 함유하는 화장료 조성물 | |
| CN115400065A (zh) | 一种具有保湿、抗皱、抗衰、舒缓、修复多功效的护肤品组合物及其应用 | |
| CN116763702A (zh) | 一种淡化深层斑点的组合物及其制备方法与应用 | |
| CN111728886A (zh) | 一种美白组合物及其制备方法和应用 | |
| Tseng et al. | Coffee pulp supplement affects antioxidant status and favors anti‐aging of skin in healthy subjects | |
| CN104323966A (zh) | 黄金水疗组合物及其使用方法 | |
| JP6122605B2 (ja) | 美白方法及びメラニン合成抑制剤のスクリーニング方法 | |
| CN115068384A (zh) | 一种快速美白组合物及其应用 | |
| EP4003282B1 (en) | Treatment of aging or uv-damaged skin | |
| KR102530481B1 (ko) | 오스톨을 포함하는 피부 노화 방지용 피부외용제 조성물 | |
| KR101349246B1 (ko) | 인삼 열매 추출물을 함유하는 피부미용증진용 건강기능보조식품 조성물 | |
| CN114533613A (zh) | 一种美白化妆品组合物及其制备方法和应用 | |
| CN113876626A (zh) | 一种对蓝光诱导皮肤细胞损伤具有保护作用的组合物及其在化妆品中的应用 | |
| Yonei et al. | Verification of improvement of periorbital wrinkles by using Asakado Skin Care | |
| FR3072878A1 (fr) | Utilisation cosmetique d'un extrait d'ivoire vegetal (phytelephas sp.) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |